Wattenberg MM, et al. - Researchers report the outcomes of bevacizumab therapy in the treatment of advanced hepatocellular carcinoma (HCC). Twelve patients with advanced HCC with intolerance of or progression during sorafenib therapy were administered bevacizumab monotherapy (5-10 mg/kg every 2-3 weeks) prior to Food and Drug Administration (FDA) approval of second-line therapy for advanced HCC, from 2008 until 2017. Findings offered a rationale for further prospective inquiry of bevacizumab as a treatment option for advanced HCC. Good tolerability of bevacizumab therapy was evident. A grade 3-4 treatment-related adverse event (transient ischemic attack) occurred in only 1/12 patients, and treatment discontinuation due to adverse events was reported in only 2/12 patients. The median overall survival of 20.2 months and a disease control rate of 54% was reported, with a median time to radiologic progression of 10.4 months.